{'fraction_non_alphanumeric': 0.03254769921436588, 'fraction_numerical': 0.007856341189674524, 'mean_word_length': 5.510948905109489, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The progestasert system--a 24-month-long active spiral. Clinical experiences with an intrauterine progesterone-releasing system].

The Biograviplan (IUD) is a therapeutic system which, from a reservoir of 52 mg progesterone, permits the programmed release of the hormone within the uterus. It provides effective contraception over a period of 24 months. Spotting, intensified and prolonged menstrual bleeding can, in common with other IUDs, occur initially. Later, hypomenorrhoea and, occasionally, also silent menstruation extending over up to 3 cycles, can be seen. Dysmenorrhoea and menstrual pain are markedly reduced as compared with other IUDs. No intrauterine pregnancy was observed, but several extrauterine pregnancies occurred. Patients should be carefully selected for such a device, which can be recommended in particular for women with primary dysmenorrhoea or hypermenorrhoea.